Provided by Tiger Fintech (Singapore) Pte. Ltd.

Compass Therapeutics, Inc.

1.94
-0.1800-8.49%
Post-market: 1.92-0.0200-1.03%19:41 EDT
Volume:878.09K
Turnover:1.73M
Market Cap:268.27M
PE:-5.40
High:2.15
Open:2.11
Low:1.91
Close:2.12
Loading ...

With 42% stake, Compass Therapeutics, Inc. (NASDAQ:CMPX) seems to have captured institutional investors' interest

Simply Wall St.
·
18 Mar

Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025

Insider Monkey
·
02 Mar

Analysts’ Top Healthcare Picks: Compass Therapeutics (CMPX), LENSAR (LNSR)

TIPRANKS
·
28 Feb

Compass Therapeutics Q4 EPS $(0.11) Misses $(0.10) Estimate

Benzinga
·
27 Feb

Compass Therapeutics reports Q4 EPS (11c), consensus (9c)

TIPRANKS
·
27 Feb

Compass Therapeutics Inc.: 2024-End Cash & Marketable Securities Expected to Provide Cash Runway Into Q1 2027

THOMSON REUTERS
·
27 Feb

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update

GlobeNewswire
·
27 Feb

Guggenheim Initiates Compass Therapeutics at Buy With $12 Price Target

MT Newswires Live
·
24 Feb

Compass Therapeutics Inc. : Guggenheim Initiates Coverage With Buy Rating; Price Target $12

THOMSON REUTERS
·
24 Feb

Compass Therapeutics initiated with a Buy at Guggenheim

TIPRANKS
·
24 Feb

Piper Sandler Initiates Compass Therapeutics at Overweight

MT Newswires Live
·
19 Feb

BUZZ-Piper Sandler initiates coverage on Compass Therapeutics with 'overweight' rating

Reuters
·
19 Feb

Compass Therapeutics Initiated at Overweight by Piper Sandler

Dow Jones
·
19 Feb

Buy Rating for Compass Therapeutics Driven by Promising Tovecimig Results and Strategic Pipeline

TIPRANKS
·
19 Feb

Compass Therapeutics Inc. : Piper Sandler Initiates Coverage With Overweight Rating; Target Price $12

THOMSON REUTERS
·
19 Feb

Optimistic Buy Rating for Compass Therapeutics Due to Promising CTX-009 Trial Results and Market Potential

TIPRANKS
·
11 Feb

Compass Therapeutics price target raised to $8 from $7 at Jefferies

TIPRANKS
·
11 Feb

Compass Therapeutics Inc. : Jefferies Raises Target Price to $8 From $7

THOMSON REUTERS
·
10 Feb

Dell Stock Set to Benefit From AI and Cloud Applications, Analyst Says. Plus, Twilio, Tradeweb, and More. -- Barrons.com

Dow Jones
·
11 Jan

Compass Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
10 Jan